Navigation Links
First evidence that obesity gene is risk factor for melanoma

The research shows that people with particular variations in a stretch of DNA within the FTO gene, called intron 8, could be at greater risk of developing melanoma.

Variations in a different part of the FTO gene, called intron 1, are already known to be the most important genetic risk factor for obesity and overeating. These variants are linked to Body Mass Index (BMI) a measure of a person's shape based on their weight and height. Having a high BMI can increase the risk of various diseases including type 2 diabetes, kidney disease, womb (endometrial) cancer and more.

But this research is the first to reveal that the gene affects a disease melanoma which isn't linked to obesity and BMI.

The results, published in Nature Genetics, suggest that FTO has a more wide-ranging role than previously suspected, with different sections of the gene being involved in various diseases.

Study author, Dr Mark Iles, Cancer Research UK scientist at the University of Leeds, said: "This is the first time to our knowledge that this major obesity gene, already linked to multiple illnesses, has been linked to melanoma. This raises the question whether future research will reveal that the gene has a role in even more diseases?

"When scientists have tried to understand how the FTO gene behaves, so far they've only examined its role in metabolism and appetite. But it's now clear we don't know enough about what this intriguing gene does.

"This reveals a hot new lead for research into both obesity-related illnesses and skin cancer."

The researchers examined tumour samples in more than 13,000 melanoma patients and almost 60,000 unaffected people from around the world.

Malignant melanoma is the fifth most common cancer in the UK with around 12,800 new cases and around 2,200 deaths each year.

Dr Julie Sharp, Cancer Research UK's senior science information manager, said: "These are fascinating early findings that, if confirmed in further research, could potentially provide new targets for the development of drugs to treat melanoma.

"Advances in understanding more about the molecules driving skin cancer have already enabled us to develop important new skin cancer drugs that will make a real difference for patients.

"But it doesn't detract from the importance of reducing your risk of the disease by enjoying the sun safely on winter breaks abroad and avoiding sunbeds. Getting a painful sunburn just once every two years can triple the risk of melanoma."


Contact: Rachel Barson
University of Leeds

Related medicine news :

1. Researchers describe first functional HIV cure in an infant
2. Zoloft Lawsuit News: Bernstein Liebhard LLP Notes New Pretrial Order in Federal Zoloft Litigation Establishing Tentative Date for First Bellwether Trial
3. Geoff Neupert, StrongFirst Master Kettlebell Instructor, Releases New Video Detailing How To Make Seemingly Unlimited Progress With Only One Kettlebell
4. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
5. U.N. Secretary-General Appoints Ray Chambers as His First Special Envoy for the Financing of the Health-Related Millennium Development Goals
6. Geoff Neupert, StrongFirst Master Kettlebell Instructor, Releases New Video Showing the Best Upper Body Exercises to Use in Traditional Kettlebell Workouts
7. NYC Chiropractor Will Soon be the First Chiropractor in New York to Offer ISCS 2.0 Non Surgical Spinal Decompression
8. Educational First Steps Hosts Early Childhood Education Conference and Symposium for Over 500 Early Childhood Professionals
9. The Triangle’s First Orthopaedic Ambulatory Surgery Center Officially Opens in Brier Creek
10. $3.35 Million Awarded in First Transvaginal Mesh Trial Verdict: Prompts Support Expansion
11. OHSU scientists first to grow liver stem cells in culture, demonstrate therapeutic benefit
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: